SCHEMBL2936003

SCHEMBL2936003

CCCC/C(=C/OC(=O)O)OC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.38
CES2 O00748 1/20 0.38
ALDH1A1 P00352 4/20 0.35
AKR1B1 P15121 1/20 0.35
TP53 P04637 1/20 0.35
GPR84 Q9NQS5 7/20 0.34
PPARG P37231 7/20 0.34
PPARD Q03181 7/20 0.34
PPARA Q07869 7/20 0.34
HDAC11 Q96DB2 5/20 0.34
TSHR P16473 4/20 0.34
PTPN1 P18031 3/20 0.34
TLR2 O60603 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
FABP4 P15090 2/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
MEN1 O00255 1/20 0.34
ESR1 P03372 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701507 0.88 ALDH1A1 (0.39) CES1CES2ALDH1A1TSHR
SCHEMBL153165 0.81 FFAR3 (0.35)
SCHEMBL4433667 0.78 CES1 (0.39) CES1CES2ALDH1A1AKR1B1TP53
SCHEMBL28340666 0.72 GPR84 (0.47) CES1CES2ALDH1A1AKR1B1GPR84
SCHEMBL28642380 0.72 GPR84 (0.47) CES1CES2ALDH1A1AKR1B1GPR84
SCHEMBL2931727 0.71
SCHEMBL1492145 0.70 DGKA (0.48) CES1CES2TSHR
SCHEMBL1492147 0.70 DGKA (0.48) CES1CES2TSHR
SCHEMBL4345308 0.70 EP300 (0.47) ALDH1A1GPR84PPARGPPARDPPARA
SCHEMBL4482819 0.70 ALDH1A1 (0.52) CES1CES2ALDH1A1AKR1B1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260128376-A1 NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE GS YUASA INT LTD (JP) 2026-05-07 US disclosed
EP-4726840-A1 NONAQUEOUS ELECTROLYTE POWER STORAGE ELEMENT AND METHOD FOR MANUFACTURING SAME GS Yuasa International Ltd. (JP) 2026-04-15 EP disclosed
EP-4583230-A1 NONAQUEOUS ELECTROLYTE POWER STORAGE ELEMENT GS Yuasa International Ltd. (JP) 2025-07-09 EP disclosed
WO-2025121377-A1 POSITIVE ELECTRODE ACTIVE MATERIAL COATING MATERIAL AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
WO-2025120994-A1 SECONDARY BATTERY NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY PROVIDED WITH SAME ステラケミファ株式会社 2025-06-12 WO disclosed
EP-3771014-B1 NONAQUEOUS ELECTROLYTE SOLUTION FOR POWER STORAGE DEVICES TOMIYAMA PURE CHEMICAL INDUSTRIES LTD (JP) 2025-03-05 EP disclosed
CN-116508173-B Method for producing nano-silicon, negative electrode active material for lithium ion battery, negative electrode for lithium ion battery, and lithium ion battery 法马特科有限公司 2024-12-24 CN disclosed
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices TOMIYAMA PURE CHEMICAL INDUSTRIES, LTD. (JP) 2024-11-26 US disclosed
WO-2024225237-A1 ELECTROLYTE FOR POWER STORAGE DEVICE, REINFORCING AGENT, ELECTROLYTE SOLUTION, AND POWER STORAGE DEVICE USING SAME 富山薬品工業株式会社 2024-10-31 WO disclosed
WO-2024225238-A1 ELECTROLYTE FOR POWER STORAGE DEVICE, REINFORCING AGENT, ELECTROLYTE SOLUTION, AND POWER STORAGE DEVICE USING SAME 富山薬品工業株式会社 2024-10-31 WO disclosed
EP-1952476-B1 USE OF AN INHIBITOR OF REDUCTION OF LIFE CYCLE OF A REDOX SHUTTLE ADDITIVE FOR A NON-AQUEOUS ELECTROLYTE AND A SECONDARY BATTERY LG CHEMICAL LTD (KR) 2010-09-15 EP disclosed
EP-2130246-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M Innovative Properties Company (US) 2009-12-09 EP disclosed
EP-2130245-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS, AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M Innovative Properties Company (US) 2009-12-09 EP disclosed
US-20090053589-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS, AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY 2009-02-26 US disclosed
WO-2008106280-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS, AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-09-04 WO disclosed
WO-2008106288-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-09-04 WO disclosed
US-20080206631-A1 ELECTROLYTES, ELECTRODE COMPOSITIONS AND ELECTROCHEMICAL CELLS MADE THEREFROM 3M INNOVATIVE PROPERTIES COMPANY 2008-08-28 US disclosed
EP-1952476-A1 INHIBITOR OF REDUCTION OF LIFE CYCLE OF REDOX SHUTTLE ADDITIVE AND NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY COMPRISING THE SAME LG Chem, Ltd. (KR) 2008-08-06 EP disclosed
WO-2007049888-A1 INHIBITOR OF REDUCTION OF LIFE CYCLE OF REDOX SHUTTLE ADDITIVE AND NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2007-05-03 WO disclosed
US-20070092802-A1 INHIBITOR OF REDUCTION OF LIFE CYCLE OF REDOX SHUTTLE ADDITIVE AND NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY COMPRISING THE SAME LG CHEM, LTD. (KR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260128376-A1 NONAQUEOUS ELECTROLYTE ENERGY STORAGE DEVICE CACNA2D1, CACNA2D3, CACNA2D4 CES1 3484/4885CES2 2359/4885ALDH1A1 4753/4885
US-12155037-B2 Nonaqueous electrolyte solution for power storage devices AQP1, NCS1, SLC9A1 CES1 2149/4885CES2 1451/4885ALDH1A1 1681/4885
US-20070092802-A1 INHIBITOR OF REDUCTION OF LIFE CYCLE OF REDOX SHUTTLE ADDITIVE AND NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY COMPRISING THE SAME SQOR, TST, SULT1E1 CES1 799/4885CES2 590/4885ALDH1A1 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.